검색어 : 통합검색[659.1]
총 1,003건 중 1,000건 출력
, 5/100 페이지
-
41
- Endomorphin analogs with analgesic actions mediated through exon 11 variants of the mu opioid receptor (MOR‐1) (659.10)
- Marrone, Gina; Grinnell, Stephen; Pan, Ying‐ Xian; Pintar, John; Majumdar, Susruta; Pasternak, Gavril; Molecular Pharmacology and Chemistry Program Memorial Sloan Kettering Cancer Center New York NY United States; Molecular Pharmacology and Chemistry Program Memorial Sloan Kettering Cancer Center New York NY United States; Molecular Pharmacology and Chemistry Program Memorial Sloan Kettering Cancer Center New York NY United States; UMDNJ/RWJMS Piscataway NJ United States; Molecular Pharmacology and Chemistry Program Memorial Sloan Kettering Cancer Center New York NY United States; Molecular Pharmacology and Chemistry Program Memorial Sloan Kettering Cancer Center New York NY United States; (The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, v.28, 2014, pp.659.10)
-
42
- ΔF659 and F659S substitutions at the HS1 of FKS2 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against Candida glabrata
- Mesquida, Aina; Dí az-Garcí a, Judith; Sá nchez-Carrillo, Carlos; Martí n-Rabadá n, Pablo; Alcalá , Luis; Muñ oz, Patricia; Escribano, Pilar; Guinea, Jesú s; ; (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, v.28, 2022, pp.1154.e5-1154.e8)
-
43
- A phase 1b study to evaluate TAK-659 in combination with nivolumab in patients (pts) with advanced solid tumors.
- Juric, Dejan; Faucette, Stephanie; Wang, Ling; Niu, Huifeng; Kannan, Karuppiah; Stumpo, Kate; Rong, Yuanxin; Shou, Yaping; Nemunaitis, John J.; Massachusetts General Hospital Cancer Center, Boston, MA; ; Millennium Pharmaceuticals, Inc., Cambridge, MA; ; Takeda Pharmaceuticals International Co., Cambridge, MA; ; Millennium Pharmaceuticals, Inc., Cambridge, MA; ; Takeda Pharmaceuticals Inc, Cambridge, MA; ; Millennium Pharmaceuticals, Inc., Cambridge, MA; ; Millennium Pharmaceuticals, Inc., Cambridge, MA; ; Millennium Pharmaceuticals, Inc., Cambridge, MA; ; Mary Crowley Cancer Research Center, Dallas, TX; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.35, 2017, pp.TPS3104-TPS3104)
-
44
- Art 107/1, 108 AEUV; VO (EG) Nr 659/1999 über besondere Vorschriften für die Anwendung von Art [ 108 AEUV]:
- ; ; (Wirtschaftsrechtliche Blätter : WBL, v.31, 2017, pp.586-588)
-
45
- Equity and Efficiency?, Lynn Davies. 1990. Falmer Press, New York, NY. 232 pages. ISBN: 1-85000-659-8. $18.95
- ; ; (Bulletin of science, technology & society, v.13, 1993, pp.47-47)
-
46
- FrB4 Optical Frequency Standard at 1.3 mum and 659 nm based on an Iodine-Stabilized Nd:YAG Laser
- Hong, F.-L.; Bi, Z.-Y.; Guo, R.; Ishikawa, J.; Kurosu, T.; Onae, A.; Matsumoto, H.; Nakagawa, K.; ; (CPEM ... digest, v.2002, 2002, pp.572-573)
-
47
- Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients With IgA Nephropathy : FR-PO659
- Barratt, Jonathan; Kooienga, Laura; Agha, Irfan; Thomas, Hanna; Workeneh, Biruh; Iyer, Sai Prasad N.; Narayanan, Rangaraj; Sathaliya, Taher; Sorensen, Bess; Schwartz, Brian S.; King, Andrew J.; University of Leicester, Leicester, United Kingdom; Colorado Kidney Care, Denver, CO; Dallas Renal Group, Dallas, TX; Dallas Renal Group, Dallas, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Chinook Therapeutics Inc, Seattle, WA; Chinook Therapeutics Inc, Seattle, WA; Chinook Therapeutics Inc, Seattle, WA; Chinook Therapeutics Inc, Seattle, WA; Chinook Therapeutics Inc, Seattle, WA; Chinook Therapeutics Inc, Seattle, WA; (Journal of the American Society of Nephrology : JASN, v.33, 2022, pp.503-503)
-
48
- Substitution F659G in the Irr1p/Scc3p Cohesin Influences the Cell Wall of <i>Saccharomyces cerevisiae</i>
- Cena, Agata; Orlowski, Jacek; Machula, Katarzyna; Fronk, Jan; Kurlandzka, Anna; Institute of Biochemistry and Biophysics, Polish Academy of Sciences; Institute of Biochemistry and Biophysics, Polish Academy of Sciences; Institute of Biochemistry and Biophysics, Polish Academy of Sciences; Institute of Biochemistry, Warsaw University; Institute of Biochemistry and Biophysics, Polish Academy of Sciences; (Cell structure and function, v.32, 2007, pp.1-7)
-
49
- Abstract 659: Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors
- Miura, Akihiro; Sootome, Hiroshi; Komori, Toshiharu; Ochiiwa, Hiroaki; Hirai, Hiroshi; ; (Cancer research : the official organ of the American Association for Cancer Research, Inc, v.80, 2020, pp.659-659)
-
50
- Moderate-Intensity Exercise Increases Subsequent Muscle Oxygenation and Speeds VO2 Kinetics in Chronic Heart Failure : 659 June 2 1:00 PM - 1:15 PM
- Bowen, T Scott; Cannon, Daniel T.; Murgatroyd, Scott R.; Witte, Klaus K.; Rossiter, Harry B.; ; (Medicine and science in sports and exercise, v.42, 2010, pp.23)
QUICK MENU
